HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.

AbstractINTRODUCTION:
T-614 is a novel oral antirheumatic agent for the treatment of rheumatoid arthritis. Whether it has immunomodulatory or disease-modifying properties and its mechanism of action are largely undetermined.
METHODS:
Rats with collagen-induced arthritis (CIA) were treated with T-614 (5 and 20 mg/kg) daily. Animals receiving methotrexate (1 mg/kg every 3 days) and the nonsteroidal anti-inflammatory agent nimesulide (10 mg/kg per day) were used as controls. A combination therapy group was treated with both T-614(10 mg/kg per day) and methotrexate (1 mg/kg every 3 days). Hind paw swelling was evaluated and radiographic scores calculated. Serum cytokine levels were assessed by Bio-plex analysis. Quantitative PCR was used to evaluate expression of mRNA for interferon-gamma, IL-4 and IL-17. Serum IL-17 and anti-type II collagen antibodies (total IgG, IgG1, IgG2a, IgG2b and IgM) were measured using ELISA.
RESULTS:
Oral T-614 inhibited paw swelling and offered significant protection against arthritis-induced cartilage and bone erosion, comparable to the effects of methotrexate. CIA rats treated with T-614 exhibited decreases in both mRNA expression of IL-17 in peripheral blood mononuclear cells and lymph node cells, and circulating IL-17 in a dose-dependent manner. T-614 also reduced serum levels of tumor necrosis factor-alpha, IL-1beta and IL-6. A synergistic effect was observed for the combination of methotrexate and T-614. In addition, T-614 (20 mg/kg per day) depressed production of anti-type II collagen antibodies and differentially affected levels of IgG2a subclasses in vivo, whereas IgM level was decreased without any change in the IgG1 level. Together, the findings presented here indicate that the novel agent T-614 has disease-modifying effects against experimental arthritis, as opposed to nimesulide.
CONCLUSIONS:
Our data suggested that T-614 is an effective disease-modifying agent that can prevent bone/cartilage destruction and inflammation in in CIA rats. Combination with methotrexate markedly enhances the therapeutic effect of T-614.
AuthorsFang Du, Liang-jing Lü, Qiong Fu, Min Dai, Jia-lin Teng, Wei Fan, Shun-le Chen, Ping Ye, Nan Shen, Xin-fang Huang, Jie Qian, Chun-de Bao
JournalArthritis research & therapy (Arthritis Res Ther) Vol. 10 Issue 6 Pg. R136 ( 2008) ISSN: 1478-6362 [Electronic] England
PMID19019215 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzopyrans
  • Inflammation Mediators
  • Sulfonamides
  • T 614
  • Methotrexate
Topics
  • Animals
  • Arthritis, Experimental (blood, pathology, prevention & control)
  • Benzopyrans (pharmacology, therapeutic use)
  • Cartilage, Articular (drug effects, immunology, pathology)
  • Drug Therapy, Combination
  • Female
  • Inflammation Mediators (therapeutic use)
  • Knee Joint (drug effects, immunology, pathology)
  • Methotrexate (therapeutic use)
  • Rats
  • Rats, Wistar
  • Sulfonamides (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: